Tag: HUTCHMED (China)

Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China

Raghuram Kadari- January 24, 2023

Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More

HUTCHMED begins HMPL-A83 phase 1 trial in advanced malignant neoplasms

- July 18, 2022

HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is ... Read More